{"nctId":"NCT00675103","briefTitle":"Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients","startDateStruct":{"date":"2008-05"},"conditions":["Chronic Gout Refractory to Conventional Therapy"],"count":7,"armGroups":[{"label":"pegloticase","type":"EXPERIMENTAL","interventionNames":["Drug: pegloticase 8 mg i.v."]}],"interventions":[{"name":"pegloticase 8 mg i.v.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previous treatment in studies of pegloticase i.v.\n* Last exposure to pegloticase i.v. greater than one year prior to study entry\n* Symptomatic gout\n* Documented hyperuricemic (SUA ≥ 7 mg/dL)\n\nExclusion Criteria:\n\n* Prior exposure to Elitek® (rasburicase)\n* Unstable angina\n* Uncontrolled arrhythmia or hypertension\n* Non-compensated congestive heart failure\n* End stage renal disease requiring dialysis\n* Concomitant use of SUA lowering agents and use of other investigational drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Event Profile","description":"Number of participants reporting events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Plasma Uric Acid","description":"This endpoint assessed the change in mean PUA concentration from baseline after the first dose and after the third dose. Mean PUA was calculated from samples collected at 5 timepoints following each of those doses. For example, Mean PUA at Week 3 included 5 timepoints before dose 2 infusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"1.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"2.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"5.61"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Gout (flare)","Infusion-Related Reaction","Arthralgia","Fatigue","Oedema Peripheral"]}}}